A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Inclusion Criteria: 1. Ability to understand and voluntarily agrees to participate by giving written informed consent for the study; 2. Patients with histologically or cytologically confirmed unresectable solid tumors; 3. At least one measurable lesion was identified per RECIST 1.1; 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; 5. Adequate organ functions as defined per protocol; 6. Minimum life expectancy of 3 months. Exclusion Criteria: 1. Patients with known active central nervous system (CNS) metastases; 2. History of other malignancy within the past 5 years, with exceptions defined in the protocol; 3. Patients with uncontrolled cancer pain; 4. Patients with serious cardiovascular and/or cerebrovascular diseases; 5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion; 6. Patients with Severe infections within 4 weeks prior to the first dose; 7. Active pulmonary tuberculosis infection; 8. History of immunodeficiency; 9. History of autoimmune diseases; 10. The adverse events of previous antineoplastic therapy did not recover to CTCAE≤ grade 1; 11. Pregnant or nursing women, or planned to become pregnant during the study period; 12. Known allergic to any component of investigational drugs.